Novel Tests

Explore our research into novel biomarker testing

Pan-ProBNP

Pan-ProBNP measures NT-proBNP and its various forms in the blood. NT-proBNP is released by the heart in response to increased strain and is produced alongside BNP, a hormone that helps reduce this strain by relaxing blood vessels and promoting the removal of excess salt and water. Elevated Pan-ProBNP levels in the blood may therefore reflect increased stress on the heart.

Pan-ProBNP

Why Pan-ProBNP matters

NT-proBNP is an established biomarker used to support the diagnosis and monitoring of heart failure. Measurement is recommended when heart failure is suspected, particularly in people presenting with symptoms such as shortness of breath. Higher levels increase the likelihood of heart failure, although results alone cannot confirm a diagnosis. Elevated levels can also occur in people with chronic kidney disease or chronic obstructive pulmonary disease (COPD). Reduced clearance of NT-proBNP by the kidneys, fluid retention and the subsequent additional strain on the heart may contribute to these increases. A high NT-proBNP or pan-proBNP result in someone with CKD should not be ignored, as it may still indicate stress on the heart. Even in the absence of diagnosed heart failure, raised NT-proBNP levels may be associated with a greater risk of future cardiovascular problems, including heart attack, stroke and heart failure.

Ready To Transform Your Laboratory Services?

Elevate your healthcare provider experience. Speak with us today to discuss your health service needs.

Book A Call Today Drop Us A Message

More Novel Tests

Amphiregulin

arrow_forward_ios

Heparin-Binding EGF-Like Growth Factor (HB-EGF)

arrow_forward_ios

Transforming Growth Factor Alpha (TGF-α)

arrow_forward_ios

Dickkopf-1 (DKK-1)

arrow_forward_ios

Programmed Cell Death Protein 1 (PD-1)

arrow_forward_ios

Mesothelin

arrow_forward_ios

Soluble Receptor for Advanced Glycation End Products (sRAGE)

arrow_forward_ios

Galectin-3

arrow_forward_ios

Monomeric CRP (mCRP)

arrow_forward_ios

Interleukin-18 (IL-18)

arrow_forward_ios

Free PSA Isoforms

arrow_forward_ios

HER2 ECD

arrow_forward_ios

Pancreastatin

arrow_forward_ios

References

ACC/AHA Joint Committee Members. (2022). 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a reportof the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, e895-e1032. Chi, S. Y. (2012). Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease. Lung, 271-276. ESC Scientific Document Group. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 3599-3726. Gupta, D. K. (2015). Natriuretic peptides and cardiometabolic health. Circulation Journal, 1647-1655. Kistorp, C. R. (2005). N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA, 1609-1616. Labaki, W. W. (2018). NT-proBNP in stable COPD and future exacerbation risk: analysis of the SPIROMICS cohort. Respiratory Medicine, 87-93. Lai, S. D. (2015). Early markers of cardiovascular risk in chronic kidney disease. Renal Failure, 254-261. McCullough, P. A. (2003). B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Reviews in Cardiovascular Medicine, 72-80. Mueller, C. M.-G. (2019). Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European Journal of Heart Failure, 715-731. Mueller, T. G. (2005). Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart, 606-612. National Institute for Health & Care Excellence. (2018). Chronic heart failure in adults: diagnosis and management. Retrieved from https://www.nice.org.uk/guidance/ng106. Spanaus, K. S.-t.-M. (2007). B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clinical Chemistry, 1264-1272. Su, X. L. (2023). NT-proBNP in different patient groups of COPD: A systematic review and meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease, 811-825. Vickery, S. P. (2005). B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertophy. American Journal of Kidney Diseases: the official journal of the National Kidney Foundation, 610-620. Wang, T. J. (2004). Plasma natriuretic peptide levels and the risk of cardiovascular events and death. The New England Journal of Medicine, 655-663. Zhao, Y. Z. (2023). The association of plasma NT-proBNP level and progression of diabetic kidney disease. Renal Failure, 2158102.